Effects of a proton pump inhibitor, omeprazole, on gastric secretion and gastric and duodenal ulcers or erosions in rats

1984 ◽  
Vol 29 (5) ◽  
pp. 394-401 ◽  
Author(s):  
Osamu Yamamoto ◽  
Yukiko Okada ◽  
Susumu Okabe
Keyword(s):  
Proton Pump Inhibitor ◽  
Gastric Secretion ◽  
Proton Pump ◽  
Duodenal Ulcers

Effects of the Proton Pump Inhibitor, E3810, on Gastric Secretion and Gastric and Duodenal Ulcers or Erosions in Rats

1991 ◽  
Vol 3 (5) ◽  
pp. 328-332 ◽  
Author(s):  
Hideaki Fujisaki ◽  
Hisashi Shibata ◽  
Kiyoshi Oketani ◽  
Manabu Murakami ◽  
Masatoshi Fujimoto ◽  
...  
Keyword(s):  
Proton Pump Inhibitor ◽  
Gastric Secretion ◽  
Proton Pump ◽  
Duodenal Ulcers

scholarly journals Does the rapid healing of duodenal ulcers mean longer remissions?

1998 ◽  
Vol 4 (3) ◽  
pp. 554-559
Author(s):  
W. Ahmed
Keyword(s):  
Proton Pump Inhibitor ◽  
Proton Pump ◽  
Response To Therapy ◽  
Duodenal Ulcers ◽  
H2 Blockers ◽  
Rapid Healing ◽  
Relapse Rates

A study was conducted to test the response to therapy and the relapse rates of endoscopically-confirmed duodenal ulcers. Endoscopy to check for healing was performed at 4 and 8 weeks in cases receiving H2-blockers and misoprostol and at 14 and 28 days in cases receiving a proton pump inhibitor. Endoscopy was repeated at 1, 3, 6 and 12 months to check for relapses. Healing rates were 61%-77% and 75%-85% at 4 and 8 weeks in the group receiving H2-blockers and misoprostol. Healing rates were 68% and 100% at days 14 and 28 with the proton pump inhibitor. The relapse rates within 3 months were 72%-86% and 100% respectively. This study indicates that the faster the ulcer healed, the earlier the relapse occurred

scholarly journals A Case of Multiple Esophageal, Gastric and Duodenal Ulcers Due to Highly Suspected Gastrinoma with Proton Pump Inhibitor Resistance

1995 ◽  
Vol 47 (0) ◽  
pp. 166-167
Author(s):  
Keisuke Kato ◽  
Masahiko Onda ◽  
Shunji Kato ◽  
Youichirou Hirose ◽  
Takashi Shirakawa ◽  
...  
Keyword(s):  
Proton Pump Inhibitor ◽  
Proton Pump ◽  
Duodenal Ulcers ◽  
Inhibitor Resistance

scholarly journals Comparative characteristics of proton pump inhibitor effectiveness in the treatment of gastric ulcer and duodenal ulcer

2020 ◽  
Vol 33 (2) ◽  
pp. 57-60
Author(s):  
Olesya P. Balitska ◽  
Tamara A. Germanyuk ◽  
Yuliia M. Hryhoruk ◽  
Tatiana I. Ivko ◽  
Yuliia O. Tomashevska ◽  
...  
Keyword(s):  
Duodenal Ulcer ◽  
Gastric Ulcer ◽  
Proton Pump Inhibitor ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Inhibitory Effect ◽  
Pharmaceutical Market ◽  
Duodenal Ulcers ◽  
Treatment Regimens

AbstractAim. The aim of this study is to evaluate the efficiency of proton pump inhibitors in the treatment of gastric and duodenal ulcers as based on literature.Materials and methods: The materials of this research are the results of 86 original studies on the effectiveness of proton pump inhibitors analysis.Methods. Descriptive, statistical, retrospective.Results and Conclusion. According to the clinical random researches, Omeprazole preparations are not included in the list due to proven better effectiveness of Esomeprazole drugs. Moreover, lansoprazole drugs are not included according to proven short-acid inhibitory effect. In addition, the brand of mentioned above preparation does not exist on the pharmaceutical market of Ukraine. Furthermore, rabeprazole preparations are presented in the research by Pariet (brand) and by the effective generic Barol, while pantoprazole preparations are represented in the research by Kontrolok (brand) and by the generic Pultset, as well as by Nolpaza. Herein, the Pantosan effect was not significantly different from the effect of Pultset and Nolpaza, but the preparation is much more expensive. In terms of efficiency (%), 4 week repair of mucosal defects was carried out by way of the following treatment regimens: Barol + Amoxicillin + Clarythromycin (90.9±6.2), Pariet + Amoxicillin + Clarythromycin (83±2.6), Kontrolok + Amoxicillin + Clarythromycin (100±1.3), Pultset + Amoxicillin + Clarythromycin (88±4.1), Nolpaza + Amoxicillin + Clarythromycin (72±4.1), Ezolonh + Amoxicillin + Clarythromycin (87.7±3.8), Neksium + Amoxicillin + Clarythromycin (96.1±3.1).

scholarly journals SAT-121 Secretin Stimulation Test in a Patient Receiving Proton PUMP Inhibitor Therapy- to Do or Not to Do?

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Parvathy Madhavan ◽  
Hassaan Aftab ◽  
Beatriz Tendler
Keyword(s):  
Proton Pump Inhibitor ◽  
Proton Pump ◽  
Gastrin Level ◽  
Proton Pump Inhibitor Therapy ◽  
Stimulation Test ◽  
Duodenal Ulcers ◽  
Ulcer Disease ◽  
History Of ◽  
Secretin Stimulation ◽  
Chronic Nausea

Abstract Introduction: Complications of gastrinoma cause increase in mortality in patients with MEN syndrome. There are concerns that secretin stimulation test (SST) can produce false positive results in the setting of proton pump inhibitor (PPI) use. However, withholding the PPI treatment in a patient with severe peptic ulcer disease can be potentially unsafe. There is also a theoretical concern that abrupt withdrawal of PPI will cause a surge in gastrin. Here we discuss a case where SST yielded impressive results despite the use of PPI. Case report: 78 y.o. Caucasian male presented in December 2018 with chronic nausea, vomiting, diarrhea of 5-year duration. Further evaluation showed severe esophagitis with strictures, multiple gastric and duodenal ulcers and he was initiated on PPI. He also had h/o hyperparathyroidism diagnosed 2 years ago s/p parathyroidectomy (2 of 4 parathyroid glands removed) and one kidney stone in his late 20s and early 70s. He had no family history of any endocrine issues. Physical examination was unremarkable. Labs were significant for gastrin levels (nl <100 pg/mL) of 375 pg/mL in 6/2016 and 219 pg/mL in 11/2018. SST was performed on 12/22/2018 which showed gastrin levels as follows: -10 min=405 pg/mL, - 5 min=404 pg/mL, + 2 min=3201 pg/mL, + 5 min=3439 pg/m, +10 min=2445 pg/mL, +20 min=1218 pg/mL, +30 min=578 pg/mL. He was diagnosed with gastrinoma based on the SST results. Genetic testing did not show any pathogenic sequence variants or deletions/duplications identified in MEN-1; CASR; CDC73; CDKN1B or RET. Given history of hyperparathyroidism and gastrinoma, he was clinically diagnosed with MEN1 syndrome. Ga-68 DOTATATE scan in May 2019 revealed focal radiotracer avidity in the tail the pancreas suspicious for neuroendocrine tumor and multiple radiotracer avid retroperitoneal and abdominal lymph nodes. Focal radiotracer avid lesion was also noted in the sacrum suspicious for osseous metastatic disease. He was started on lantreotide monthly injections in July 2019. Gastrin level decreased to 94 pg/mL 1 week after first injection, however later increased to 304 pg/ml 1 week after third dose of lantreotide. Surgical options are also being explored. Conclusion: An increase in more than 120pg/mL over basal gastrin level within 10 min in SST is consistent with a diagnosis of gastrinoma. Our patient demonstrated an impressive increase in gastrin level with SST while on PPI therapy. Pertinent diagnostic information was successfully obtained without increasing the risk of complications that can occur by withdrawal of PPI therapy.

Sign in / Sign up

Export Citation Format

Share Document